抗体药物偶联物研发中的关键生物分析测量：药代动力学/药效学建模人员的观点 - Suppr

Suppr

超能文献

Key bioanalytical measurements for antibody-drug conjugate development: PK/PD modelers' perspective.

作者信息

Shah Dhaval K, Barletta Frank, Betts Alison, Hansel Steven

出版信息

Bioanalysis. 2013 May;5(9):989-92. doi: 10.4155/bio.13.78.

DOI:10.4155/bio.13.78

PMID:23641690

Abstract

摘要

相似文献

Key bioanalytical measurements for antibody-drug conjugate development: PK/PD modelers' perspective.

Bioanalysis. 2013 May;5(9):989-92. doi: 10.4155/bio.13.78.

Insights into antibody-drug conjugates: bioanalysis and biomeasures in discovery.

Bioanalysis. 2013 May;5(9):985-7. doi: 10.4155/bio.13.65.

Strategies to address drug interaction potential for antibody-drug conjugates in clinical development.

Bioanalysis. 2013 May;5(9):1115-30. doi: 10.4155/bio.13.76.

Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper.

Bioanalysis. 2013 May;5(9):997-1006. doi: 10.4155/bio.13.38.

Bioanalysis special focus issue on antibody-drug conjugates.

Bioanalysis. 2013 May;5(9):981-3. doi: 10.4155/bio.13.68.

Synthesis, bioanalysis and biodistribution of photosensitizer conjugates for photodynamic therapy.

Bioanalysis. 2013 May;5(9):1099-114. doi: 10.4155/bio.13.37.

PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine.

Bioanalysis. 2013 May;5(9):1025-40. doi: 10.4155/bio.13.72.

Immunogenicity and PK/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis.

Bioanalysis. 2014 Jan;6(1):79-87. doi: 10.4155/bio.13.302.

Integration of bioanalytical measurements using PK-PD modeling and simulation: implications for antibody-drug conjugate development.

Bioanalysis. 2015;7(13):1633-48. doi: 10.4155/bio.15.85.

Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.

Pharm Res. 2015 Nov;32(11):3508-25. doi: 10.1007/s11095-015-1626-1. Epub 2015 Feb 11.

引用本文的文献

Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates Administered via Subcutaneous and Intratumoral Routes.

Pharmaceutics. 2023 Apr 3;15(4):1132. doi: 10.3390/pharmaceutics15041132.

Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice.

Pharm Res. 2022 Jan;39(1):1-24. doi: 10.1007/s11095-021-03162-1. Epub 2022 Jan 19.

Measurement and Mathematical Characterization of Cell-Level Pharmacokinetics of Antibody-Drug Conjugates: A Case Study with Trastuzumab-vc-MMAE.

Drug Metab Dispos. 2017 Nov;45(11):1120-1132. doi: 10.1124/dmd.117.076414. Epub 2017 Aug 18.

Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.

AAPS J. 2016 Sep;18(5):1101-1116. doi: 10.1208/s12248-016-9929-7. Epub 2016 May 19.

Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.

Pharm Res. 2015 Nov;32(11):3508-25. doi: 10.1007/s11095-015-1626-1. Epub 2015 Feb 11.

Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.

AAPS J. 2015 Jan;17(1):35-43. doi: 10.1208/s12248-014-9684-6. Epub 2014 Nov 8.

Protective effect of different anti-rabies virus VHH constructs against rabies disease in mice.

PLoS One. 2014 Oct 27;9(10):e109367. doi: 10.1371/journal.pone.0109367. eCollection 2014.

A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate.

AAPS J. 2014 May;16(3):452-63. doi: 10.1208/s12248-014-9576-9. Epub 2014 Mar 1.

World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA.

MAbs. 2014 Jan-Feb;6(1):18-29. doi: 10.4161/mabs.27437.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验